Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-05-05
1999-02-23
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514778, 514964, 514965, 536103, A61K 31735, C07H 1312, C08B 3716
Patent
active
058744185
ABSTRACT:
Sulfoalkyl ether-cyclodextrin (SAE-CD) based pharmaceutical formulations are provided by the present invention. These formulations comprise SAE-CD derivatives and a therapeutic agent, a major portion of which is not complexed to the SAE-CD. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative can be used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents.
REFERENCES:
patent: 3426011 (1969-02-01), Parmerier et al.
patent: 3816393 (1974-06-01), Hayashi et al.
patent: 4497803 (1985-02-01), Harada et al.
patent: 4535152 (1985-08-01), Szejtli et al.
patent: 4555504 (1985-11-01), Jones
patent: 4582900 (1986-04-01), Brandt et al.
patent: 4596795 (1986-06-01), Pitha
patent: 4638058 (1987-01-01), Brandt et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4746734 (1988-05-01), Tsuchiyama et al.
patent: 4764604 (1988-08-01), Muller
patent: 4774329 (1988-09-01), Friedman
patent: 4808232 (1989-02-01), Beesley
patent: 4869904 (1989-09-01), Uekama et al.
patent: 5134127 (1992-07-01), Stella et al.
Pharmaceutical Dosage Forms --Tablets, vol. 1, 2nd Edition, Herbert A. Lieberman, ed., pp. 372-376, 1990.
Okimoto, et al., "The Interaction of Charged and Uncharged Drugs with Neutral (HP-.beta.-CD) and Anionically Charged (SEB7-.beta.-CD) .beta.-Cyclodextrins," Pharmaceutical Research, 13(2) :256-264, 1996.
Muller, et al., "Cyclodextrin Derivatives for Solubilisation, Stabalisation, and Absorption of Drugs," Proceedings of the Fourth International Symposium on Cyclodextrins, pp. 369-382, 1988.
Pitha, Josef, "Amorphous Water Soluble Derivatives of Cycodextrins: From Test Tube to Patient," Third International on Recent Advances in Drug Delivery Systems, pp. 1-12, 1987.
Brewster, et al., "Improved Delivery Through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified .beta.-Cyclodextrins," J. Pharm. Sci., 77(11):981-985, Nov. 1988.
Muranushi, et al., "Studies on Benexate CD: Effect of Inclusion Compound Formation on the Anti-Ulcer Activity of Benexate, the Effective Ingredient in Benexate CD," Folia Pharmacol. Japan, 91(6):377-383, 1988.
Torres-Lanbandeira, et al., "Biopharmaceutical Stability of the Glibornuride/.beta.-Cyclodextrin Inclusion Complex After One Year of Storage," S.T.P. Pharma. Sciences, 4(3) :235-239, 1994.
Peri, et al., "Inclusion Complexes of Tolnaftate with .beta.-Cyclodextrin and Hydroxypropyl .beta.-Ctckidextrub ," Drug Development and Industrial Pharmacy, 20(8):1401-1410, 1994.
Otero-Espinar, et al., "Oral Bioavailability of Naproxen-.beta.-Cyclodextrin Inclusion Compound," Internat. J. of Pharmaceutics, 75: 37-44, 1991.
Lin, et al., "Solid Particulates of Drug --.beta.-Cyclodextrin Inclusion Complexes Directly Prepared by a Spray-Drying Technique," Intern. J. of Pharmaceutics, 56:249-259, 1989.
Esclusa-Diaz, et al., "Preparation and Evaluation ofKetoconazole --.beta.-Cyclodextrin Multicomponent Complexes," Intern. J. of Pharmaceutics, 142:183-187, 1996.
McGinity James W.
Rajewski Roger A.
Stella Valentino
Cydex, Inc.
Kunz Gary L.
Matos Rick
LandOfFree
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formula does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfoalkyl ether cyclodextrin based solid pharmaceutical formula, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfoalkyl ether cyclodextrin based solid pharmaceutical formula will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307042